Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS)

Table 2 Median and range of the grouped sub-scores (Voiding and Incontinence) and the individual symptom scores for nocturia, urgency and frequency from the ICIQ LUTS questionnaires (MLUTS and FLUTS for males and females respectively) by treatment, with p-values and standardized effect size, d

Measure	Treatment
	A: Placebo		B: Melatonin		p	d
	Median	Range	Median	Range	p	d
Voiding sub-score	4.0	0–12	2.0	0–12	0.096	0.492
Incontinence (Storage) sub-score	3.0	0–9	3.0	0–12	0.107	0.450
Nocturia	2.0	1–3	2.0	1–3	0.892	0.037
Urgency	2.0	0–3	2.0	1–4	0.772	0.079

ISSN: 1471-2377